Items where Funder is Bristol Myers Squibb.
Up a level09/91/21
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
12/35/07
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
A19121
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
A23814
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
A25447
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
C7852/A19772
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
CV185-741
Wilkinson, C, Wu, J orcid.org/0000-0001-6093-599X, Clegg, A orcid.org/0000-0001-5972-1097 et al. (4 more authors) (2022) Impact of oral anticoagulation on the association between frailty and clinical outcomes in people with atrial fibrillation: Nationwide primary care records on treatment analysis. EP Europace, 24 (7). euac022. pp. 1065-1075. ISSN 1099-5129
L387
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
Not Known
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
PRISM
Bhaskaran, D., Savage, J., Patel, A. et al. (9 more authors) (2024) A randomised phase II trial of temozolomide with or without cannabinoids in patients with recurrent glioblastoma (ARISTOCRAT): protocol for a multi-centre, double-blind, placebo-controlled trial. BMC Cancer, 24 (1). 83. ISSN 1471-2407
Buckley, HL orcid.org/0000-0002-9829-5817, Collinson, FJ, Ainsworth, G et al. (15 more authors) (2019) PRISM protocol: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. BMC Cancer, 19. ARTN: 1102. ISSN 1471-2407
Collinson, F, Brown, S, Buckley, H orcid.org/0000-0002-9829-5817 et al. (11 more authors) (2018) PRISM: A randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma. Annals of Oncology (Part of special issue:Abstract Book of the 43rd ESMO Congress (ESMO 2018) 19–23 October 2018, Munich, Germany), 29 (8). viii331-viii331. ISSN 0923-7534
Vasudev, N.S. orcid.org/0000-0001-8470-7481, Ainsworth, G., Brown, S. et al. (24 more authors) (2023) Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM). Journal of Clinical Oncology. ISSN 0732-183X